



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Optical Molecular Imaging of Inflammatory Cells in Interventional Medicine-An Emerging Strategy

Citation for published version:

Birch, GP, Campbell, T, Bradley, M & Dhaliwal, K 2019, 'Optical Molecular Imaging of Inflammatory Cells in Interventional Medicine-An Emerging Strategy', *Frontiers in Oncology*, vol. 9, 882.
<https://doi.org/10.3389/fonc.2019.00882>

Digital Object Identifier (DOI):

[10.3389/fonc.2019.00882](https://doi.org/10.3389/fonc.2019.00882)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Frontiers in Oncology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Optical Molecular Imaging of Inflammatory Cells in Interventional Medicine—An Emerging Strategy

Gavin P. Birch^{1,2*}, Thane Campbell^{2*}, Mark Bradley¹ and Kevin Dhaliwal²

¹ EaStChem School of Chemistry, University of Edinburgh, Edinburgh, United Kingdom, ² Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

The optical molecular imaging of inflammation is an emerging strategy for interventional medicine and diagnostics. The host's inflammatory response and adaptation to acute and chronic diseases provides unique signatures that have the potential to guide interventions. Thus, there are emerging a suite of molecular imaging and sensing approaches for a variety of targets in this area. This review will focus on two key cellular orchestrators that dominate this area, neutrophils and macrophages, with recent developments in molecular probes and approaches discussed.

OPEN ACCESS

Edited by:

David Leslie Carr-Locke,
Weill Cornell Medicine, Cornell
University, United States

Reviewed by:

Wagner Fontes,
University of Brasilia, Brazil
Guolin Ma,
China-Japan Friendship
Hospital, China

*Correspondence:

Gavin P. Birch
gavin.birch@ed.ac.uk
Thane Campbell
s1003032@sms.ed.ac.uk

Specialty section:

This article was submitted to
Cancer Imaging and Image-directed
Interventions,
a section of the journal
Frontiers in Oncology

Received: 05 June 2019

Accepted: 27 August 2019

Published: 12 September 2019

Citation:

Birch GP, Campbell T, Bradley M and
Dhaliwal K (2019) Optical Molecular
Imaging of Inflammatory Cells in
Interventional Medicine—An Emerging
Strategy. *Front. Oncol.* 9:882.
doi: 10.3389/fonc.2019.00882

Keywords: molecular imaging, inflammation, interventional medicine, optical imaging, macrophage, neutrophil

INTRODUCTION

Recent developments in optical molecular imaging are enabling the identification and evaluation of inflammatory cells such as macrophages and neutrophils in a variety of imaging scenarios. This is important as these leukocytes are an important part of host defense and immune homeostasis. Their pivotal roles as professional phagocytes in acute and chronic inflammatory disease may allow their use as versatile interventional biomarkers and as such fluorescent imaging of these cells has the potential to advance disease treatment and management, by producing sub-cellular information in real-time.

Intrinsic tissue autofluorescence adds further value when the structures of extracellular matrix or metabolic activities are of interest. The predominant modality of fluorescence intensity measurements, coupled with recent technological developments such as label-free non-linear optical images and Raman analyses (1, 2), have opened up the possibility of giving the surgeon functional images of the surgical site in real time. Furthermore, exciting developments are resulting from the integration of cell classification and machine learning techniques, allowing deeper analysis of the richness of imaging datasets.

Macroscopic widefield open fluorescence systems and high-resolution endomicroscopy are the predominant systems that have been used clinically to detect optical molecular tracers. The recent advances in imaging technology mean that fluorescence guided surgery is becoming a reality for cancer resection (3). Complete tumor removal is crucial for patient outcomes, but difficult to ensure by conventional microscopy as visual characteristics and palpitation are inadequate to determine tumor-free margin. With fluorescence systems, surgeons have the future ability to assess the extent of tumor excision and local metastases in real-time using a fluorescent label that “lights-up” the tumor and hence delineates its margins. Optical endomicroscopy (OEM) enables optical imaging at high resolution typically via a bundle of optical fibers (although rapidly being replaced by chip-on-tip technologies) to enable imaging with microscopic resolution, with the added ability to explore within a variety of cavities. Recently fiber-bundle endomicroscopy has been used in the lung to

assess alveolar structure in emphysema, neoplastic changes in epithelial cells and real-time *in vivo* detection of bacteria (4–6). As well as in the GI tract, where it has been used to detect changes associated with squamous cell carcinoma and colorectal polyps (7). There are a range of OEM platforms, spanning clinical use and developmental systems (6, 8), although standardization is necessary to generate meaningful diagnostic data (9).

Alongside the devices that enable real-time fluorescence imaging capability, optical molecular probes are required that provide contrast and are suitable for use *in vivo*. Although extensive libraries of optical agents for many targets have been developed (10, 11), none have been licensed for routine clinical use. This review will focus on fluorescent molecular probes for inflammatory cells, in particular neutrophils and macrophages. Recent agents allow the identification of these cells, as well as providing information on dynamic cellular processes such as enzymatic activity, redox processes, and phagocytic ability; processes that impact pathophysiology. Overall, inflammatory cell imaging creates an ideal paradigm for patient-specific disease monitoring and intervention (Table 1). Recent advances in the fluorescent and Raman imaging are enabling macrophage and neutrophil burden and activity to be described non-invasively and dynamically with tissue-level resolution.

NEUTROPHILS AS BIOMARKERS

As cells that migrate to diseased tissues and accumulate, both over the course of a disease and due to chemotactic stimuli, neutrophils can provide meaningful prognostic data just by their enumeration. Neutrophil counts have long been used to stratify patients by scoring disease, for example in ulcerative colitis (25). Several large patient studies and systematic reviews show the neutrophil to lymphocyte ratio is useful in staging inflammatory bowel disease (IBD) and numerous solid tumors (13, 14), as well as predicting cardiovascular disease, diabetic neuropathy, sepsis-induced acute kidney injury, glaucoma and bacteremia (15–19, 26). Simple neutrophil enumeration may even resolve the controversial question of when to intervene in carotid artery disease (27). Using explanted human tissues Ionita et al. evidenced correlations between neutrophil count and several critical factors in atherosclerotic plaque stability (28).

Of course, more sophisticated insights can be drawn from considering the viability status of neutrophils and quantifying neutrophil extracellular traps (NETs) independently of neutrophils in altered activation states. The accumulation of neutrophils on the ocular surface in dry-eye disease (DED) is thought to result in pathological NET formation (29). With the recent success of a phase I/II study evaluating DNase treatment for DED, NET burden is becoming an important clinical parameter in this disease (30). Also, neutrophil nuclei

TABLE 1 | Evidence for the role of neutrophils and macrophages as biomarkers in various diseases.

Cell	Information	Disease	References
Neutrophil	Disease stage	Gastrointestinal tumors	(12)
		Solid tumors	(13)
		Inflammatory bowel disease	(14)
	Disease onset	Bacteremia	(15)
		Sepsis-induced acute kidney injury	(16)
		Cardiovascular	(17)
	Critical event	Diabetic neuropathy	(18)
		Chronic obstructive pulmonary disease	(19)
		Pesticide poisoning	(20)
Macrophage	Disease stage	Solid tumors	(21)
		Sentinel lymph node metastasis (breast cancer)	(22)
		Rheumatoid arthritis	(23)
		Liver fibrosis	(24)

Data referenced to meta-analyses or patient studies in the literature.

undergo morphological changes in DED that can assist the detection of DED-related hyperosmolarity (31). Due to the abundance of human neutrophil elastase (HNE) in NETs (32) and this enzyme's stimulatory role in mucin production (33), HNE may allow diagnostic disease monitoring in DED. Beyond the conjunctiva, neutrophil infiltration is inversely correlated with neuroprotection D1 and their pro-inflammatory activity has clear implications in retinal vascular and neural degeneration (34). Tumor associated neutrophils (TANs) play a wide array of roles and their investigation can reveal where they act in opposition. For example, in early stage lung cancer TANs were shown to help limit disease progression however animal models have elucidated several pro-tumoral mechanisms (35, 36). Some of the heterogeneity measured may come from relying on the expression of TAN markers which can vary in different tumor microenvironments and no suitable marker exists for distinguishing between the N1 and N2 phenotypes (37).

Another layer of insight may be accessible via measurement of neutrophil activity, as studies of patients with inflammatory bowel disease have demonstrated. Patient studies found changes in fecal lactoferrin, calprotectin and the protease HNE were significantly correlated with endoscopy and could be used to distinguish between mild disease, mucosal healing and clinical remission, and even predict flare onset (38). HNE is further implicated in IBD treatment by cleaving therapeutic monoclonal antibodies Infliximab, Adalimumab, Vedolizumab (39). The varied and clear benefits of such simple and direct analyses highlight the precision of the inflammatory response and the diagnostic potential of optical probes for neutrophil imaging.

NEUTROPHIL IMAGING PROBES

Neutrophils are the first leukocytes to be recruited to an inflammatory site. Their capacities to respond en masse and

Abbreviations: DiD, A lipophilic carbocyanine dye; FAM, Carboxyfluorescein; FITC, Fluorescein isothiocyanate; FLIM, Fluorescence lifetime imaging microscopy; FRET, Förster resonant energy transfer; FR, Folate receptor; HNE/NE, (Human) neutrophil elastase; IBD, Inflammatory bowel disease; MMP, Matrix metalloproteinase; MMR, Macrophage mannose receptor; NIR, Near infrared; OEM, Optical endomicroscopy; PET, Positron emission tomography; TPME, Two-photon endomicroscopy; UC, Ulcerative colitis.

TABLE 2 | Overview of optical probes for imaging neutrophils.

Target	Molecule class	Optical modality	Models	References
Serprocidins	Quenched dendrimeric probe	Fluorescence	Human cells <i>ex vivo</i>	(40)
HNE	Quenched probe	Fluorescence	Mouse	(41)
	Quenched dendrimeric probe	Fluorescence	Sheep, human	(42)
FPR1	Peptide	Fluorescence	Human	(43)
	Radioactive nanoparticle	Dual PET/MRI	Mouse	(44)
Nucleus	Label-free	Raman	Human cells <i>ex vivo</i>	(45)
	Label-free	2-photon FLIM	Human	(46)

rapidly underscore their potential as biomarkers capable of producing large readouts in short time-frames—properties that are particularly desirable for surgical guidance. The relatively short neutrophil half-life acts to limit any off-target consequences of labeling to days or hours, whilst the persistence of the neutrophilic influx in inflamed tissues makes neutrophil readouts useful over the entire disease monitoring period, irrespective of its duration. Overall, neutrophil imaging creates an ideal paradigm for patient-specific disease monitoring and intervention. Recent advances in the fluorescent and Raman spectroscopic modes of optical imaging are, for the first time, enabling neutrophil burden and activity to be described non-invasively and dynamically with tissue-level resolution (Table 2).

Proteases

Human neutrophil elastase (HNE) is a serprocidin stored at millimolar concentrations in the azurophil granules of neutrophils (47). Although HNE is chiefly a microbicidal protease, its broad substrate specificity allows neutrophils to use it intracellularly, extracellularly and in membrane-bound form for a variety of purposes. Phagocytosis, extravasation (48), extracellular matrix remodeling (49–51), cell-signaling (52), mucus production (53), mucociliary function, (54), and NETosis (55) all have roles for HNE and a host of further interactions give the enzyme utility for other cell-types including monocytes, endothelial, and adenocarcinoma cells. When released by activated neutrophils HNE can be used to destroy pathogens and promote neovascularization as part of tissue repair, however sustained HNE release contributes to the pathophysiological sequelae of acute respiratory distress syndrome, lung adenocarcinoma, atherosclerosis and other chronic inflammatory diseases.

Craven et al. recently reported a probe that revealed neutrophil activation. This was designed to detect the serine proteases (serprocidins) using a pan-serprocidin substrate. A tribranched probe was developed which maintains an optically super-silent ground state with a methyl red and fluorescein FRET pair on each of its three branches (Figure 1A) (40). The structure facilitates internalization by activated neutrophils and once in the phagolysosome, active serprocidins cleave the peptide sequences to remove the methyl red quenchers and generate a large fold increase in fluorescence (Figure 1B). The probe generates bright intracellular puncta, in human neutrophils, within seconds

of activation with pharmacological stimulus or bacterial co-incubation. By adding the probe to whole blood in a simple, no-wash, no-lyse, flow cytometric assay, activated neutrophils could be profiled (Figure 1C). Combining rapid signal generation and detailed cell-type specific analysis situates this pan-serprocidin probe as a promising patient-stratification biomarker for several chronic inflammatory diseases.

The neutrophil elastase probe NE680 is a near-infrared multi-branched probe which is sensitive to cleavage by murine NE and HNE, amongst others (Figure 2) (41). It consists of a peptide sequence (PMAVVQSVP) flanked by NIR fluorophores and conjugated to a polylysine dendrimer, which lengthens its plasma and tissue half-lives and results in internal quenching. Upon cleavage by proteases, NIR fluorescence emission is generated. NE680's quantification of NE activity was demonstrated by incubating lung sections, from LPS/fMLF challenged mice, in increasing doses of the NE-specific inhibitor, sivelestat (Figures 2C,D). Non-invasive, quantitative NE imaging was demonstrated using fluorescence molecular tomography (41). Wang et al. demonstrated a similar dose dependent reduction in NIR fluorescence of NE680 could be achieved under more physiologically relevant conditions, using recombinant alpha 1-antitrypsin (a1PI) instead of sivelestat (56). Further studies using NE680 have revealed roles for NE in promoting neutrophil accumulation in atherosclerotic plaques, insulin resistance and arthritic pain, in murine models (57–59). Although NE680 cleavage by HNE has been demonstrated *in vitro*, structural differences between the murine and human NE active sites and functional differences between murine and human neutrophils mean the clinical utility of NE680 has yet to be demonstrated.

Although a wealth of neutrophil probes have not reached *in vivo* studies, exciting developments in optical probe design provide discriminatory power between related proteases. Despite their concomitant release from degranulating neutrophils, the various serprocidins perform distinct molecular functions (60). Screening combinations of natural and unnatural amino acids by their kinetic affinity and rate constants, Kasperkiewicz et al. designed a HNE probe with a 100-fold sensitivity over the previous champion substrate designed by Korkmaz et al. (61). The group's combinatorial substrate library technique generated substrate-based activatable probes and inhibitory, targeted probes and their approach included counter selection which biases against the interference of substrate cleavage from




FIGURE 1 | Structure of Craven's neutrophil probe (A) before and (B) after cleavage by active HNE and indicating the resulting FAM fluorescence. (C) In a no-wash, no-lyse whole blood flow cytometric assay, neutrophils activated with bacterial products take up Probe (8) and upregulate CD11b. Fluorescent signal is blocked in activated neutrophils with 100 μ M sivelestat co-incubation. MFI = Geometric mean fluorescent index. * $P < 0.05$, ** $P < 0.01$, exact multiplicity adjusted p values are shown with the figure. (C) Reproduced under the CC BY 4.0 license (40).

similar protease families (62, 63). Finally, the recently synthesized fluorogenic toolbox contained unique substrate-fluorophore combinations for each of the four neutrophil serine proteases (HNE, proteinase 3, cathepsin G and neutrophil serine protease 4) and revealed for the first time their uneven distributions in azurophil granules (64).

To enable clinical, functional neutrophil imaging via HNE activity at inflammatory sites a Neutrophil Activation Probe (NAP) was developed (42). Using static quenching NAP's tribranched structure holds fluorescein moieties in close proximity limiting fluorescence. Each of these SmartProbe's three branches contain an HNE substrate sequence cleaved by the active enzyme to generate large fold increases in fluorescent intensity. Encouraging results with NAP came from synthesizing the SmartProbe to GMP standards and endomicroscopically imaging neutrophil activation in ventilated and perfused *ex vivo* human lungs (37). Craven et al. found NAP to be dequenched within the phagolysosome specifically in response to NE and this led to a successful phase 1 clinical study (NCT01532024) (42). The ability of NAP to inform clinical decision making is currently being investigated in the phase 2 clinical study, SNAP-IT (number: NCT02804854). SNAP-IT will evaluate the utility of imaging NAP-illuminated neutrophils, endomicroscopically, in intensive care unit patients.

Formyl Peptide Receptor 1

NIR imaging is often superior to other wavelengths as tissue autofluorescence is lowest in this region of the visible spectrum. Zhou et al. synthesized a NIR fMLF receptor 1 targeting nanoprobe for imaging inflammation (Figure 3) (43). The issue of inflammatory site access was solved by building the labeling (cFLFLF) and fluorophore (Oyster-800) components onto a hydrophilic 8-arm PEG scaffold. There are many benefits to using the cFLFLF ligand: its high affinity FPR1 binding ($K_d = 2$ nM) generates a sensitive readout of leukocyte distribution (65). The ability of cFLFLF probes to access inflammatory sites with either PET (^{64}Cu , $^{99\text{m}}\text{Tc}$) or NIR (Cy5, Cy7) labels has also been demonstrated. However FPR1 is not cell-type specific and these probes bound macrophages (66) and neutrophils (67, 68). cFLFLF probes may generate a useful readout when information on inflammatory cell accumulation is sought in broad terms but may fail to clarify whether clinical intervention should focus on altering neutrophil or macrophage activity.

Pellico et al. created neutrophil-specific radiotracers with dual PET and MRI signals by coating gallium-doped nanoparticles with cFLFLF for FPR1 labeling (44). Coating with peptide can produce significant probe hydrophobicity which has prevented other radiotracers from reaching the inflammatory site. By citrate-coating nanoparticles, the relatively large nanoparticle




FIGURE 2 | Schematic representation of NE680 FAST before (A) and after (B) cleavage by active NE which alleviates fluorescence quenching. (C) Fluorescence molecular tomography of NE680 FAST (4 nM intranasal) instilled into control, LPS/fMLP and LPS/fMLP mice treated with inhibitor. NIR signal is absent in untreated controls and reduced in sivelestat (5 mg/kg intranasal) treated controls (D) and mean concentration of fluorescence (in nM) was quantified in the lung area ROIs (orange cubes) for control ($N = 12$), LPS/fMLP ($N = 16$), and sivelestat ($N = 12$) groups. (C,D) Copyright 2011 Kossodo et al. Reproduced under the CC BY 3.0 license (41).

surface confers the necessary solubility for targeting neutrophils *in vivo*. Although neutrophil depletion was capable of removing signal, it also removes important cross-talk from the LPS inflammatory response.

A truly neutrophil specific target has proved elusive. Instead neutrophil specificity has arisen from combinatorial strategies exploiting the unique confirmations of certain targets within neutrophils. For example, HNE reaches such high concentrations in neutrophils that most systems will fail to detect the minority of HNE positive monocytes which bears far lower quantities of the enzyme. Neutrophil specific functions can also be exploited by careful probe design. Phagolysosome alkalisation does not occur in monocytes and enhance the fluorescence signal of some fluorophores. The super-silent FRET probe combines these structural and functional cellular characteristics to achieve neutrophil specificity. Label-free methods of cell identification have also sought neutrophils using targets found in other cell types but uniquely arranged in neutrophils.

Label Free Neutrophil Imaging

Neutrophil imaging in the context of inflammatory research has aimed at understanding the relevance of cellular components to cell function. Questions of molecular colocalization and characterization are well-served by fluorescent labels for elucidating the spatiotemporal relationships of cells and subcellular structures without altering the processes for investigation. As translational research influences surgical guidance questions of long-term cytotoxicity and ease-of-adoption are more important. Label free imaging, which may seem imprecise for research purposes, is often cheaper, safer and does not require the considerable translation effort of alternative techniques. Molecules such as NADH, elastin, and hemoglobin have been claimed to provide intracellular and extracellular autofluorescence, but signals from cells will always be an amalgamation of signatures of multiple and complex analytes. There is still much characterization to generate clinically meaningful autofluorescence imaging and techniques such as




FIGURE 3 | fMLF receptor targeting nanoprobe were implanted in control and neutrophil depleted mice, neutrophils were labeled and quantified. **(A)** Image of hematoxylin and eosin staining and quantification of inflammatory cells. **(B)** Immunohistochemistry and quantification of neutrophils. **(C)** Fluorescence intensities over 4 h post-injection showing the diminished accumulation of the nanoprobe in neutrophil depleted mice compared to control. H&E, hematoxylin and eosin; IHC, immunohistochemistry; PLA, poly(lactic acid); * $P < 0.05$, ** $P < 0.01$. Copyright 2012 Zhou et al. Reproduced under the CC BY-NC 3.0 license (43).

fluorescence lifetime imaging may become an important source of differentiation. Reflectance microscopy, which distinguishes between matter of different refractive indices, is now also capable of cellular resolution. For high-resolution imaging, individual molecules can be detected and quantified via Raman spectroscopy. Label free imaging is en route to becoming as informative as fluorescence image-guided surgery can be, a limit it may exceed in a multi-modal platform.

Raman Spectroscopy

By measuring the minute proportion of photons which interact with molecules inelastically, Raman spectroscopy can, non-destructively, describe the chemical composition of unlabeled matter. The first look at a leukocyte using Raman spectroscopy was when Puppels et al. compared eosinophils and Chinese hamster lung cells (69). The group found nuclei spectroscopically distinct from cytoplasm and that distinctions between granulocytes may be made on the basis of their cytoplasmic contents (70). In 1998, Otto et al. collected the first Raman spectrum of activated neutrophils (71). More recently, Ramoji et al. demonstrated the ability to discern between lymphocytes and neutrophils with concomitant Raman mapping of nuclear morphology (45). Using principal components analysis, cells could be classified with 94% accuracy in the validation dataset and predicted with 81% accuracy in a new dataset from a completely different donor. As Raman spectroscopy can describe intracellular contents it may be better suited to quantifying cell function. Instead of identifying cells, Harz et al. used spectrally distinct Raman and fluorescence excitation wavelengths to successfully multiplex these spectroscopic and microscopic techniques (2). Particularly in such a multiplexed system, intracellular localization and oxidation states of functionally significant molecules may be revealed through Raman mapping to imitate whether or not neutrophils are effecting processes such phagocytosis and to what extent (72).

Two-Photon Endogenous FLIM

The question of whether or not technology as nascent and complex as two-photon microscopy can be translated into a clinical endomicroscopy technology is unanswered. Although confocal endomicroscopy is in clinical use, two-photon endomicroscopy (TPEM) carries additional fiber optics challenges such as fiber non-linearity distorting the two-photon excitation light and the low quantum yields of intrinsic fluorophores (73). These and other hurdles were overcome in 2008, when TPEM of human and mouse sarcomeres was conducted using a GRIN lens (74). The technique involved a minimally-invasive needle clad fiber capable of imaging directly beneath the skin. *In vivo* TPEM was performed laparoscopically with a “stick” lens which avoids GRIN lens associated spherical aberrations revealing ovarian cancer through a laparoscopic procedure, centimeters into the body (75). However murine tissues were investigated *in vivo* with a flexible FLIM endomicroscope, of working distance 135 μm in 2011, and the field continues to rapidly improve this label-free technology (76).

Using two-photon excited fluorescence (TPEF), Zeng et al. characterized blood cells by their endogenous fluorescence lifetime signals (Figure 4). TPEF fluorescence lifetime imaging can detect differences in bound and unbound NADH such erythrocytes, agranulocytes and granulocytes are distinguishable (46). As proportions of bound and free NADH vary by the dominant metabolic pathway employed by the cell—TPEF FLIM is functional imaging. Metabolic functional imaging may be able to identify granulocytes undergoing phagocytosis but whether or not phagocytosis and other factors affecting the NAD/NADH ratio, such as oxygen availability, can be disentangled remains unclear. By visualizing cytoplasmic protein, TPEF FLIM can identify the size and shape of cells and, by exclusion, their nuclei—detailing the characteristic lobular structure of granulocyte nuclei. With neutrophils comprising 95% of the granulocytes population, these morphological distinctions give TPEF FLIM neutrophil-specificity to rival the




FIGURE 4 | TPEF showing granulocytes, agranulocytes with platelets (white arrows) and erythrocytes (a–c) under 600 nm excitation and (d–f) under 700 nm excitation, with bright field images in (d) and (e) showing blood smears granulocytes and agranulocytes with platelets. Normalized spectra of blood cell autofluorescence under 600 nm (5 mW) and 720 nm (10 mW) excitation, are seen in (g) and (h), respectively. The acquisition time for each TPEF image: 32 s; resolution: 128 × 128 pixels; scale bar: 20 μm; γ is the gamma value in the gamma correction of (e). Reproduced with permission from Zeng et al. Copyright 2013 SPIE (46).

best ligand-based, fluorescent probes. Although the distinction between phagocytic and untreated neutrophils is subtle, this technique can separate untreated from activated neutrophils on morphological grounds. Quiescent neutrophils have a rounded morphology but membrane ruffling characteristic of neutrophil activation was visualized when neutrophils phagocytosed *E. coli* (46).

MACROPHAGES AS BIOMARKERS

Macrophages are readily found at the site of inflammation or infection, forming the first defense against pathogens. Although they play a key role in the initiation of defensive inflammation, recent literature suggests they are also responsible for the resolution of inflammation and repair processes (77). Several

large studies show the role of macrophages in solid tumors, sentinel lymph node metastasis, rheumatoid arthritis and liver fibrosis (21–24). In ophthalmology, macrophages have been shown to play a role in preventing ocular infection (78) and contribute to corneal wound healing (79) and biomarkers of macrophage activity have been linked to primary open angle glaucoma and dry eye disease (80, 81).

Macrophages have been broadly classified into two different phenotypes—M1 and M2, with further subsets M2a, M2b, M2c identified, and they display plasticity by moving between these phenotypes (82). Generally, the M1 “classically activated” macrophages are seen as pro-inflammatory and exhibit killing mechanisms against microorganisms, while M2 “alternatively activated” macrophages are anti-inflammatory and exhibit wound healing functions. Further evidence shows that they

TABLE 3 | Overview of optical probes for imaging macrophages.

Target	Molecule class	Optical modality	Models	References
FR- β	Small molecule	SPECT/CT, <i>in vivo</i> imaging	Mice/Human (RA)	(85, 86)
CD206	Nanobody (sdAb)	PET	Mice	(87)
	Peptide	Fluorescence	Mice	(88)
MMP-12	Peptidomimetic	Fluorescence	Mice	(89)
Cathepsins	Quenched polymer probe	Fluorescence	Rat	(90)
	Peptide—activity probe	PET/CT and Fluorescence	Mice, Human (PET in IPF patients)	(91)





FIGURE 5 | Clinical uses of OTL38 showing whole body fluorescence imaging of a mouse bearing a FR α^+ KB tumor in color (a) and grayscale (b,d) 2 h after administering OTL38. Analysis of gray value vs. distance (c,e) [across the line from (b) or within the box from (d)]. Representative fluorescence images NSCLC and ovarian cancer during image-guided surgery 2 h after administering OTL38. (f) Preoperative CT image of pulmonary tumor nodal, (g) overlay of fluorescence image over white light image of pulmonary tumor nodal, and (h) immunohistochemical (IHC) staining of resected pulmonary tumor nodal indicating tumor is FR α^+ . Representative fluorescence images over white light images of primary and metastatic ovarian tumors in (i) uterine adnexa and (j) uterus and bladder peritoneum. LT, lung tumor; HL, healthy lung; FSF, Foerster sponge forceps; SF, surgeons fingers; C, cotton. Adapted with permission from Mahalingam et al. Copyright 2018 American Chemical Society (92).

do not rest in one polarization state, instead they may be reactivated into a different state. The ability to understand the crosstalk between macrophage activation signals and how this alters their phenotypes would be valuable in characterizing disease phenotypes. In oncology, tumor associated macrophages (TAMs) represent a significant imaging target due to their recruitment in the microenvironment of a tumor (83). Their presence contributes to the invasiveness of tumors as they have been linked to angiogenesis, cell proliferation, invasion and immune suppression (84). Targets to visualize macrophages include MMP-12, cathepsin S, the macrophage mannose receptor (CD206), and folate receptor beta (FR- β) (Table 3).

Folate Receptor Beta

Folate receptor (FR) targeting is a promising method for visualization of cells that overexpress the folate receptor. Recently, a demonstration of the capabilities of folate targeting during fluorescence guided surgery of cancer was described by Mahalingam (92). OTL-38 is an NIR labeled folate that accumulates in cancer tissue, has a high target affinity and enables the visualization of cancer tissue using image-guided surgery (Figure 5). This agent has completed Phase I and II trials for ovarian and lung cancers, and is now in Phase III clinical trials for the detection of FR $^+$ ovarian cancer (NCT03180307). For inflammatory cells, the β isoform (FR- β) is expressed on



activated macrophages and has a high affinity for its ligand folic acid ($K_d = 10^{-10}$ M) (93). Its identification on synovial macrophages in patients with rheumatoid arthritis was first described by Nakashima-Matsushita et al. (94). Studies on both rheumatoid and osteoarthritis in dogs, horses, rats, mice, and humans have demonstrated that essentially all joints experiencing active inflammation uptake folate conjugates (93). A number of studies have reported on the cellular uptake of FR targeted molecules by activated monocytes (95) and macrophages in a number of different diseases (85, 86, 96).

Xia et al. investigated the presence of the folate receptor on activated macrophages from arthritic patients (85). Fluorescence imaging was used to show that the folate receptor was a valid marker for activated macrophages, while non-activated macrophages did not express the folate receptor. After characterizing that bacteria-recruited murine macrophages expressed FR and that these were activated (upregulation of Ly-6C/G, CD80, and CD86), folate-FITC was incubated with the synovial fluid of patients with diagnosed rheumatoid arthritis. A subset of the CD11b⁺ macrophages was found to uptake folate-FITC, and competition experiments showed that this uptake could be inhibited with the non-conjugated folic acid—showing FR specificity. Finally, a technetium-radiolabelled folate (FolateScan: EC20) was utilized to perform SPECT imaging of human inflamed joints in a Phase II trial (NCT00588393).

In murine models of asthma, Shen et al. showed that *ex vivo* lung macrophages with an M2 phenotype (arginase⁺, CD206⁺) bound the green fluorescent probe, folate-Oregon Green. Further, SPECT/CT imaging of ^{99m}Tc -EC20 showed uptake in ovalbumin induced asthmatic lungs, while there was no uptake in the lungs of healthy mice (Figure 6) (86).

Recent work by Poh et al. showed that a folate liposome could act as a specific method of targeting FR⁺ immune cells, specifically in mouse models of colitis and atherosclerosis (97). This study used fluorescent DiD liposomes, labeled with folate, as a demonstration of the ability to deliver payloads via the folate receptor which can accumulate in inflamed tissues. Atherosclerotic mice (ApoE^{-/-} mice fed a high fat diet) were injected via the tail vein with 2 mg/kg of NT-liposome-DiD or Fol-liposome-DiD, respectively. Fluorescence imaging showed selective uptake of Fol-liposomes in the atherosclerotic mice.

To further our understanding of the clinical applicability of folate targeted imaging agents, the field should aim to evaluate their performance in human inflammatory models. It

is however also worth mentioning an observation from this field; the use of folate depleted media is necessary for any folate targeting cell studies due to high levels of folic acid in routine media formulations.

CD206

CD206, also known as the macrophage mannose receptor (MMR), is a well-reported marker of M2 differentiated macrophages (82). Its functional role is to recognize mannose lectins found on pathogens. A number of different approaches to probe design have been taken against CD206⁺ macrophages, from antibodies to a more recent report of a target-binding peptide. The Manocept concept of nanomolecule imaging agents targeting the lectin domain of CD206 has resulted in the FDA approval of γ -Tilmanocept, a ^{99m}Tc -labeled radiolabelled tracer for the imaging of sentinel lymph nodes (98). A similar strategy was applied by Kim et al. who developed a near-infrared MMR targeting polymer and utilized using OCT-NIRF imaging to visualize carotid atheroma plaques (99). However, mannose derivatives are not specific to CD206 and can be recognized by other mannose receptors (100). Therefore, there is a need to develop ligands that are more specific for CD206 which are more suitable for use in the clinic.

Targeted Nanobodies

The most advanced agents for CD206 targeting are labeled nanobodies, which have shown promise as molecular imaging agents (101). Nanobodies (Nb) have been developed as imaging tracers against a number of targets in oncology and inflammation due to their high affinities and small size compared to antibodies (102). Movahedi et al. produced a ^{99m}Tc -labeled nanobody against MMR with an affinity of 2 nM determined by SPR and validated its use for SPECT/micro-CT imaging of tumor-associated macrophages in preclinical models (103). SPECT/CT imaging in tumor-bearing mice showed uptake of the Nb which was significantly higher than uptake of the control Nb with analysis of the dissected tissue confirming these findings.

This nanobody was further developed by Blykers et al. as an ^{18}F -PET tracer for the detection of macrophages in tumor stroma (87). Tumor associated macrophages (TAMs) with upregulated CD206 were found to be tumor promoting. *In vitro* studies with the ^{18}F -fluorobenzoic acid (FB) labeled nanobody (anti-MMR 3.49) showed that it had a high affinity

for human MMR ($K_D = 1.8$ nM), while *in vivo* biodistribution studies showed fast renal clearance and specific retention in the tumor and MMR-expressing tissue. In a small animal PET imaging study, the nanobody was specifically recognized by MMR in 3LL-R tumor bearing mice, when compared with

the uptake in MMR-deficient mice (**Figure 7**). This ligand shows promise as a radiopharmaceutical, while in future it could be developed as an optical probe for highlighting M2 macrophages by fluorescence guided surgery. As noted by Debie et al., the fluorophore chosen and method of conjugation should be carefully considered when developing labeled nanobodies (104).




FIGURE 7 | Transverse and coronal PET/CT images of WT (left) vs. MMR-deficient (right) 3LL-R tumor-bearing mice scanned 3 h after injection of ^{18}F -FB-anti MMR 3.49. Arrows point to tumor (T), kidney (K), and bladder (B). Adapted with permission from Blykers et al. Copyright 2015 SNMMI (87).

Peptides

Fluorescent peptides are a widely utilized method for labeling receptors and a number of peptidic agents are under clinical investigation for cancer and bacterial infection imaging (10). Recently, Scodeller et al. showed that M2-like TAMs could be targeted by a “FAM-UNO” fluorescent peptide [sequence: 5(6)-FAM-Ahx-CSPGAKVRC] (88). The peptide sequence was identified by *in vivo* phage display of peptides that bound peritoneal macrophages in 4T1 tumor-bearing mice. FAM-UNO was found to target M2-like TAMs via the CD206 receptor (**Figure 8**) and this binding was confirmed by fluorescence anisotropy. Cargos were delivered to TAMs by coating polymer vesicles with the FAM-UNO peptide and these could be used as a contrast agent for sentinel lymph node imaging. Although this agent is yet to be translated to humans, it could be an attractive method for imaging TAMs. However, green autofluorescence of human tissues means alternative fluorophores may need to be considered to make a case for future clinical applications.

MMP-12

The matrix metalloproteinases (MMPs) are a family of proteases that play a key role in ECM structure, function and remodeling. In the tumor microenvironment macrophages have been found to be potent producers of MMP 2 and 9 (105). It is important to note the pioneering work of the Tsien lab and Avelas Biosciences in advancing activatable cell penetrating peptides (ACPPs) for imaging protease activity. In 2004, the lab demonstrated that an MMP-2 cleavable ACPP could detect tumor cells in resected tissue (106). More recently, Miampamba et al. developed AVB-620, a ratiometric ACPP





FIGURE 8 | FAM-UNO accumulates in CD206⁺, TIE2⁺ macrophages in breast tumors (a,b) and lymph nodes (c). 4T1 tumor bearing mice were injected i.v. with FAM-UNO (30 nmol), mice were sacrificed after 2 h and tumor tissues were analyzed by immunofluorescence: rabbit anti-FAM (green), rat anti-CD206 (red) antibodies and counterstained with DAPI. Scale: 100 μm . Reproduced under the CC BY 4.0 license (88).



with Cy5 and Cy7 fluorophores that is a substrate for MMP-2 and -9 (107). This agent has completed Phase I clinical trials for imaging breast cancer tumors in patients undergoing surgery (NCT02391194).

While there are many non-selective imaging agents for MMPs, there is a lack of selective MMP tracers and this may hamper the understanding of the role of a specific MMP in disease. For example MMP-12, macrophage elastase, is responsible for the breakdown of elastin and it is associated with a number of inflammatory pathologies such as aortic aneurysm, emphysema, and rheumatoid arthritis (108). It has been characterized as having a protective role during wound healing in injury models (109).

Bordenave et al. reported the synthesis and evaluation of a Cy5 MMP-12 probe based on a pseudopeptide (RXP470.1) which had previously been shown to inhibit atherosclerotic plaque growth *in vivo* (110). This study noted that the fluorophore used was important to the blood clearance rate and biodistribution of this probe, a factor that has been highlighted by other groups working on the development of fluorescent probes. Further optimization lead to a zwitterionic labeled probe which had good affinity to MMP-12 and fast blood clearance (89). The selectivity of this MMP inhibitor should give advantages over other pan-MMP probes in showing the specific MMP implicated in a disease. Immunostaining showed an analog (probe 2) bound to MMP-12⁺ and F4/80 macrophages (**Figure 9**). The probe was used for imaging active forms of MMP-12 in murine models. Using a sponge implantation model of sterile inflammation, increased cell infiltration was seen which correlated with mannose receptor positive macrophages. The study was also interested in the role that MMP-12 plays in aneurysm. In a model of carotid aneurysm, significant upregulation of MMP-12 was seen, along with significantly higher signal for the probe, compared to the control (**Figure 9**). Although this was only demonstrated in a mouse model, because of this probe's high selectivity and the clinical relevance of the experimental setup could allow this probe to be used in an intraoperative setting.

Cathepsins

TAMs remodel the extracellular matrix (ECM) through MMPs and cathepsins, specifically during tumor invasion (111). Onda et al. used a commercial NIR fluorescent protease-activatable probe (ProSense), in which they demonstrated imaging of cathepsin activity and confirmed its localization to macrophages. Using *in vivo* and *ex vivo* models of colon cancer they showed that infiltrating TAMs initiate tissue remodeling at the tumor margins by secreting cathepsins. ProSense signal at the tumor margin was shown to be due to cathepsin B⁺ macrophage infiltration in a rat colon model (90). However, large probes such as ProSense suffer from slow tumor uptake leading to slow rates of activation, as well as demonstrating off-target activation by other proteases which limits their applicability as a fluorescence diagnostic tool.

A number of alternative cathepsin activatable probes are under development (112, 113). Withana et al. investigated the role that macrophages play in idiopathic pulmonary fibrosis (IPF) by staining human biopsy tissue from IPF patients. The optical probe BMV109 is broadly activated by cathepsins B, S, L, and X, was used to validate pan-cathepsin labeling of sectioned frozen tissue. This showed that macrophages expressing active cathepsins were at fibrotic sites in comparison to healthy tissue which showed no cathepsin activity (91). To date, this probe has only been demonstrated in the topical labeling of IPF tissue, further investigation would be necessary to show its utility in fluorescence based diagnostics in the clinic.

CONCLUSION

The nascent field of optical molecular imaging of inflammatory cells appears to be a vibrantly innovative arena full of early-stage biomarkers that offer promise of patient benefits. Targeting neutrophils and macrophages may deliver previously inaccessible measures of disease activity across common and life-threatening diseases. Whilst, in this review, the current stage of neutrophil and macrophage imaging has been discussed, clearly other inflammatory cells such as T cells play major role

in interventional medicine. With many non-redundant targets and readouts available, probe multiplexing seems a particular advantage of this field with the potential to matching monitoring and treatment with immunological precision. As well as being informative in its own right, parallel label-free imaging may become a rapid means of interpreting labeled techniques across multiple contexts and machine learning data-reduction stands to push the power of OMI even further. An exciting therapeutic potential lies in the how imaging agents can impact the drug discovery process—with immune cells. These new technologies stand to enrich assay outputs, accelerate drug development decisions and clinical outputs, and enable better direct drug response metrics in trials.

Future studies will demonstrate the translatability of imaging agents into clinically useful optical probes. Despite the plethora of novel reagents advancing with *in vitro* investigations very few have begun the translational journey. This inertia is perhaps not surprising as the technical demands of translating novel imaging methods can become overwhelming, especially within an academic environment. Probes must be innovative enough to meet clinical needs, yet synthetically

feasible and complementary to imaging systems. This is a fiercely interdisciplinary pursuit from start to finish and nearly impossible without optical imaging device standards, as all technologies must meet safety and efficacy standards. Without standardization, investigators risk underestimating translation-ready reagents with “sub-standard” apparatus, or unnecessarily pursue doomed reagents with poor selectivity and specificity (114).

AUTHOR CONTRIBUTIONS

GB and TC wrote the manuscript. KD and MB assisted with proofreading and preparation for publication.

FUNDING

We thank the Engineering and Physical Sciences Research Council Optima CDT (grant: EP/L016559/1) and Biotechnology and Biological Sciences Research Council (grant: BB/N503940/1) for supporting this work, plus additional support from GlaxoSmithKline.

REFERENCES

- Sun Y, You S, Tu H, Spillman DR, Chaney EJ, Marjanovic M, et al. Intraoperative visualization of the tumor microenvironment and quantification of extracellular vesicles by label-free nonlinear imaging. *Sci Adv.* (2018) 4:eau5603. doi: 10.1126/sciadv.aau5603
- Harz M, Kiehnopf M, Stckel S, Rsch P, Deufel T, Popp J. Analysis of single blood cells for CSF diagnostics via a combination of fluorescence staining and micro-Raman spectroscopy. *Analyst.* (2008) 133:1416–23. doi: 10.1039/b716132h
- Zhang RR, Schroeder AB, Grudzinski JJ, Rosenthal EL, Warram JM, Pinchuk AN, et al. Beyond the margins: real-time detection of cancer using targeted fluorophores. *Nat Rev Clin Oncol.* (2017) 14:347–64. doi: 10.1038/nrclinonc.2016.212
- Yserbyt J, Dooms C, Janssens W, Verleden GM. Endoscopic advanced imaging of the respiratory tract: exploring probe-based confocal laser endomicroscopy in emphysema. *Thorax.* (2018) 73:188–90. doi: 10.1136/thoraxjnl-2016-209746
- Fuchs FS, Zirlik S, Hildner K, Schubert J, Vieth M, Neurath MF. Confocal laser endomicroscopy for diagnosing lung cancer *in vivo*. *Eur Respir J.* (2013) 41:1401–8. doi: 10.1183/09031936.00062512
- Krstajić N, Akram AR, Choudhary TR, McDonald N, Tanner MG, Pedretti E, et al. Two-color widefield fluorescence microendoscopy enables multiplexed molecular imaging in the alveolar space of human lung tissue. *J Biomed Opt.* (2016) 21:046009. doi: 10.1117/1.JBO.21.4.046009
- East JE, Vleugels JL, Roelandt P, Bhandari P, Bisschops R, Dekker E, et al. Advanced endoscopic imaging: European Society of Gastrointestinal Endoscopy (ESGE) Technology Review. *Endoscopy.* (2016) 48:1029–45. doi: 10.1055/s-0042-118087
- Thiberville L, Moreno-Swirc S, Vercauteren T, Peltier E, Cavé C, Bourg Heckly G. *In vivo* imaging of the bronchial wall microstructure using fibered confocal fluorescence microscopy. *Am J Respir Crit Care Med.* (2007) 175:22–31. doi: 10.1164/rccm.200605-684OC
- Koch M, Symvoulidis P, Ntziachristos V. Tackling standardization in fluorescence molecular imaging. *Nat Photonics.* (2018) 12:505–15. doi: 10.1038/s41566-018-0221-5
- Staderini M, Megia-Fernandez A, Dhaliwal K, Bradley M. Peptides for optical medical imaging and steps towards therapy. *Biorg Med Chem.* (2018) 26:2816–26. doi: 10.1016/j.bmc.2017.09.039
- Garland M, Yim JJ, Bogoy M. A bright future for precision medicine: advances in fluorescent chemical probe design and their clinical application. *Cell Chem Biol.* (2016) 23:122–36. doi: 10.1016/j.chembiol.2015.12.003
- Bowen RC, Ann N, Little B, Harmer JR, Ma J, Mirabelli LG, et al. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. *Oncotarget.* (2017) 8:32171–89. doi: 10.18632/oncotarget.16291
- Templeton AJ, McNamara MG, eruga B, Vera-Badillo FE, Aneja P, Ocaa A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst.* (2014) 106:dju124. doi: 10.1093/jnci/dju124
- Zhao C, Ding C, Xie T, Zhang T, Dai X, Wei Y, et al. Validation and optimization of the Systemic Inflammation-Based modified Glasgow Prognostic Score in predicting postoperative outcome of inflammatory bowel disease: preliminary data. *Sci Rep.* (2018) 8:747. doi: 10.1038/s41598-017-18771-3
- de Jager CPC, van Wijk PTL, Mathoera RB, de Jongh-Leuvenink J, van der Poll T, Wever PC. Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. *Crit Care.* (2010) 14:R192. doi: 10.1186/cc9309
- Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. Can neutrophil-lymphocyte ratio be independent risk factor for predicting acute kidney injury in patients with severe sepsis? *Renal Fail.* (2015) 37:225–9. doi: 10.3109/0886022X.2014.982477
- Angkananard T, Anothaisintawee T, Thakkinstian A. Neutrophil lymphocyte ratio and risks of cardiovascular diseases: a systematic review and meta-analysis. *Atherosclerosis.* (2017) 263:e159–60. doi: 10.1016/j.atherosclerosis.2017.06.507
- Xu T, Weng Z, Pei C, Yu S, Chen Y, Guo W, et al. The relationship between neutrophil-to-lymphocyte ratio and diabetic peripheral neuropathy in Type 2 diabetes mellitus. *Medicine.* (2017) 96:e8289. doi: 10.1097/MD.00000000000008289
- Teng F, Ye H, Xue T. Predictive value of neutrophil to lymphocyte ratio in patients with acute exacerbation of chronic obstructive pulmonary disease. *PLoS ONE.* (2018) 13:e0204377. doi: 10.1371/journal.pone.0204377
- Dundar ZD, Ergin M, Koçlu R, Ozer R, Cander B, Gunaydin YK. Neutrophil-lymphocyte ratio in patients with pesticide poisoning. *J Emerg Med.* (2014) 47:286–93. doi: 10.1016/j.jemermed.2014.01.034

21. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. *PLoS ONE*. (2012) 7:e50946. doi: 10.1371/journal.pone.0050946
22. Sondak VK, King DW, Zager JS, Schneebaum S, Kim J, Leong SPL, et al. Combined analysis of phase III trials evaluating [^{99m}Tc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. *Ann Surg Oncol*. (2013) 20:680–8. doi: 10.1245/s10434-012-2612-z
23. Cook AD, Hamilton JA. Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor- α in rheumatoid arthritis: focus on mavrilimumab. *Ther Adv Musculoskeletal Dis*. (2018) 10:29–38. doi: 10.1177/1759720X17752036
24. Friedman SL, Ratzin V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. *Hepatology*. (2018) 67:1754–67. doi: 10.1002/hep.29477
25. Bressenot A, Salleron J, Bastien C, Danese S, Boulagnon-Rombi C, Peyrin-Biroulet L. Comparing histological activity indexes in UC. *Gut*. (2015) 64:1412–8. doi: 10.1136/gutjnl-2014-307477
26. Li S, Cao W, Han J, Tang B, Sun X. The diagnostic value of white blood cell, neutrophil, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio in patients with primary angle closure glaucoma. *Oncotarget*. (2017) 8:68984–95. doi: 10.18632/oncotarget.16571
27. Biller J, Thies WH. When to operate in carotid artery disease. *Am Fam Physician*. (2000) 61:400–6. Available online at: <https://www.aafp.org/afp/2000/0115/p400.html>
28. Ionita MG, van den Borne P, Catanzariti LM, Moll FL, de Vries JP, Pasterkamp G, et al. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. *Arterio Thromb Vasc Biol*. (2010) 30:1842–8. doi: 10.1161/ATVBAHA.110.209296
29. Sonawane S, Khanolkar V, Namavari A, Chaudhary S, Gandhi S, Tibrewal S, et al. Ocular surface extracellular DNA and nuclease activity imbalance: a new paradigm for inflammation in dry eye disease. *Invest Ophthalmol Vis Sci*. (2012) 53:8253–63. doi: 10.1167/iovs.12-10430
30. Mun C, Gulati S, Tibrewal S, Chen Y-F, An S, Surenkhuu B, et al. A Phase I/II placebo-controlled randomized pilot clinical trial of recombinant deoxyribonuclease (DNase) eye drops use in patients with dry eye disease. *Transl Vis Sci Technol*. (2019) 8:10. doi: 10.1167/tvst.8.3.10
31. Tibrewal S, Ivanir Y, Sarkar J, Nayeb-Hashemi N, Bouchard CS, Kim E, et al. Hyperosmolar stress induces neutrophil extracellular trap formation: implications for dry eye disease. *Invest Ophthalmol Vis Sci*. (2014) 55:7961–9. doi: 10.1167/iovs.14-15332
32. Yoo D-g, Winn M, Pang L, Moskowicz SM, Malech HL, Leto TL, et al. Release of cystic fibrosis airway inflammatory markers from *Pseudomonas aeruginosa*-stimulated human neutrophils involves NADPH oxidase-dependent extracellular DNA trap formation. *J Immunol*. (2014) 192:4728–38. doi: 10.4049/jimmunol.1301589
33. Kohri K, Ueki IF, Nadel JA. Neutrophil elastase induces mucin production by ligand-dependent epidermal growth factor receptor activation. *Am J Physiol Lung Cell Mol Physiol*. (2002) 283:L531–40. doi: 10.1152/ajplung.00455.2001
34. Bazan NG. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. *J Lipid Res*. (2009) 50(Suppl.):S400–5. doi: 10.1194/jlr.R800068-JLR200
35. Gregory AD, McGarry Houghton A. Tumor-associated neutrophils: new targets for cancer therapy. *Cancer Res*. (2011) 71:2411–6. doi: 10.1158/0008-5472.CAN-10-2583
36. Gong L, Cumpian AM, Caetano MS, Ochoa CE, De la Garza MM, Lapid DJ, et al. Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. *Mol Cancer*. (2013) 12:154. doi: 10.1186/1476-4598-12-154
37. Wu L, Saxena S, Awaji M, Singh KR. Tumor-associated neutrophils in cancer: going pro. *Cancers*. (2019) 11:E564. doi: 10.3390/cancers11040564
38. Langhorst J, Boone J, Lauche R, Rueffer A, Dobos G. Faecal lactoferrin, calprotectin, PMN-elastase, CRP, and white blood cell count as indicators for mucosal healing and clinical course of disease in patients with mild to moderate ulcerative colitis: *post-hoc* analysis of a prospective clinical trial. *J Crohns Colitis*. (2016) 10:786–94. doi: 10.1093/ecco-jcc/jjw044
39. Kok K, Curciarello R, Soband T, Jones S, Docena G, MacDonald T. Human neutrophil elastase degrades the therapeutic monoclonal antibodies effective in IBD. *J Crohns Colitis*. (2018) 12(Suppl. 1):S146. doi: 10.1093/ecco-jcc/jjx180.232
40. Craven TH, Avlonitis N, McDonald N, Walton T, Scholefield E, Akram AR, et al. Super-silent FRET sensor enables live cell imaging and flow cytometric stratification of intracellular serine protease activity in neutrophils. *Sci Rep*. (2018) 8:1–10. doi: 10.1038/s41598-018-31391-9
41. Kossodo S, Zhang J, Groves K, Cuneo GJ, Handy E, Morin J, et al. Noninvasive *in vivo* quantification of neutrophil elastase activity in acute experimental mouse lung injury. *Int J Mol Imaging*. (2011) 2011:1–11. doi: 10.1155/2011/581406
42. Craven T, Walton T, Akram A, McDonald N, Scholefield E, Walsh T, et al. *In-situ* imaging of neutrophil activation in the human alveolar space with neutrophil activation probe and pulmonary optical endomicroscopy. *Lancet*. (2016) 387:S31. doi: 10.1016/S0140-6736(16)00418-9
43. Zhou J, Tsai YT, Weng H, Tang EN, Nair A, Dav. Real-time detection of implant-associated neutrophil responses using a formyl peptide receptor-targeting NIR nanoprobe. *Int J Nanomed*. (2012) 7:2057–68. doi: 10.2147/IJN.S29961
44. Pellico J, Lechuga-Vieco AV, Almarza E, Hidalgo A, Mesa-Nuez C, Fernandez-Barahona I, et al. *In vivo* imaging of lung inflammation with neutrophil-specific ⁶⁸Ga nano-radiotracer. *Sci Rep*. (2017) 7:1–10. doi: 10.1038/s41598-017-12829-y
45. Ramoji A, Neugebauer U, Bocklitz T, Foerster M, Kiehntopf M, Bauer M, et al. Toward a spectroscopic hemogram: Raman spectroscopic differentiation of the two most abundant leukocytes from peripheral blood. *Anal Chem*. (2012) 84:5335–42. doi: 10.1021/ac3007363
46. Zeng Y, Yan B, Sun QQ, Teh SK, Zhang W, Wen ZL, et al. Label-free *in vivo* imaging of human leukocytes using two-photon excited endogenous fluorescence. *J Biomed Opt*. (2013) 18:040504. doi: 10.1117/1.JBO.18.4.040504
47. Hirche TO, Benabid R, Deslee G, Gangloff S, Achilefu S, Guenounou M, et al. Neutrophil elastase mediates innate host protection against *Pseudomonas aeruginosa*. *J Immunol*. (2008) 181:4945. doi: 10.4049/jimmunol.181.7.4945
48. Young RE, Thompson RD, Larbi KY, La M, Roberts CE, Shapiro SD, et al. Neutrophil elastase (NE)-deficient mice demonstrate a nonredundant role for NE in neutrophil migration, generation of proinflammatory mediators, and phagocytosis in response to zymosan particles *in vivo*. *J Immunol*. (2004) 172:4493–502. doi: 10.4049/jimmunol.172.7.4493
49. Ferry G, Lonchampt M, Pennel La. Activation of MMP-9 by neutrophil elastase in an *in vivo* model of acute lung injury. *FEBS Lett*. (1997) 402:111–5. doi: 10.1016/S0014-5793(96)01508-6
50. Jackson PL, Xu X, Wilson L, Weathington NM, Clancy JP, Blalock JE, et al. Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. *Mol Med*. (2010) 16:159–66. doi: 10.2119/molmed.2009.00109
51. Oltmanns U, Sukkar MB, Xie S, John M, Chung KF. Induction of human airway smooth muscle apoptosis by neutrophils and neutrophil elastase. *Am J Respir Cell Mol Biol*. (2005) 32:334–41. doi: 10.1165/rcmb.2004-0321OC
52. Benabid R, Wartelle J, Malleret L, Guyot N, Gangloff S, Lebarry F, et al. Neutrophil elastase modulates cytokine expression: contribution to host defense against *pseudomonas aeruginosa*-induced pneumonia. *J Biol Chem*. (2012) 287:34883–94. doi: 10.1074/jbc.M112.361352
53. Shao MXG, Nadel JA. Neutrophil Elastase Induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF- α -converting enzyme. *J Immunol*. (2003) 175:4009–16. doi: 10.4049/jimmunol.175.6.4009
54. Smallman LA, Hill SL, Stockley RA. Reduction of ciliary beat frequency *in vitro* by sputum from patients with bronchiectasis: a serine proteinase effect. *Thorax*. (1984) 39:663–7. doi: 10.1136/thx.39.9.663
55. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. *J Cell Biol*. (2010) 191:677–91. doi: 10.1083/jcb.201006052

56. Wang M, Zhan Y, Chen J, Rong H, O'Neil SP, Ghosh B, et al. Understanding lung deposition of alpha-1 antitrypsin in acute experimental mouse lung injury model using fluorescence microscopy. *Int J Mol Imaging*. (2016) 2016:1–11. doi: 10.1155/2016/5768312
57. Glinzer A, Ma X, Prakash J, Kimm MA, Lohfer F, Kosanke K, et al. Targeting elastase for molecular imaging of early atherosclerotic lesions. *Atertio Thromb Vasc Biol*. (2017) 37:525–33. doi: 10.1161/ATVBAHA.116.308726
58. Talukdar S, Oh DY, Bandyopadhyay G, Li D, Xu J, McNelis J, et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. *Nat Med*. (2012) 18:1407–12. doi: 10.1038/nm.2885
59. Muley MM, Reid AR, Botz B, Blcskei K, Helyes Z, McDougall JJ. Neutrophil elastase induces inflammation and pain in mouse knee joints via activation of proteinase-activated receptor-2. *Br J Pharmacol*. (2016) 173:766–77. doi: 10.1111/bph.13237
60. Wiedow O, Meyer-Hoffert U. Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. *J Intern Med*. (2005) 257:319–28. doi: 10.1111/j.1365-2796.2005.01476.x
61. Kasperkiewicz P, Poreba M, Snipas SJ, Parker H, Winterbourn CC, Salvesen GS, et al. Design of ultrasensitive probes for human neutrophil elastase through hybrid combinatorial substrate library profiling. *Proc Natl Acad Sci USA*. (2014) 111:2518–23. doi: 10.1073/pnas.1318548111
62. Kasperkiewicz P, Kot S, Janiszewski T, Grobork K, Porba M, Snipas SJ, et al. Determination of extended substrate specificity of the MALT1 as a strategy for the design of potent substrates and activity-based probes. *Sci Rep*. (2018) 8:1–10. doi: 10.1038/s41598-018-34476-7
63. Poreba M, Solberg R, Rut W, Lunde Ngoc N, Kasperkiewicz P, Snipas Scott J, et al. Counter selection substrate library strategy for developing specific protease substrates and probes. *Cell Chem Biol*. (2016) 23:1023–35. doi: 10.1016/j.chembiol.2016.05.020
64. Kasperkiewicz P, Altman Y, D'Angelo M, Salvesen GS, Drag M. Toolbox of fluorescent probes for parallel imaging reveals uneven location of serine proteases in neutrophils. *J Am Chem Soc*. (2017) 139:10115–25. doi: 10.1021/jacs.7b04394
65. Locke LW, Chordia MD, Zhang Y, Kundu B, Kennedy D, Landseal J, et al. A novel neutrophil-specific PET imaging agent: cFLFLFK-PEG-64Cu. *J Nucl Med*. (2009) 50:790–7. doi: 10.2967/jnumed.108.056127
66. Yang X, Chordia MD, Du X, Graves JL, Zhang Y, Park YS, et al. Targeting formyl peptide receptor 1 of activated macrophages to monitor inflammation of experimental osteoarthritis in rat. *J Orth Res*. (2016) 34:1529–38. doi: 10.1002/jor.23148
67. Xiao L, Zhang Y, Berr SS, Chordia MD, Pramoonjago P, Pu L, et al. A novel near-infrared fluorescence imaging probe for *in vivo* neutrophil tracking. *Mol Imaging*. (2012) 11:372–82. doi: 10.2310/7290.2011.00054
68. Xiao L, Zhang Y, Liu Z, Yang M, Pu L, Pan D. Synthesis of the Cyanine 7 labeled neutrophil-specific agents for noninvasive near infrared fluorescence imaging. *Bioorg Med Chem Lett*. (2010) 20:3515–7. doi: 10.1016/j.bmcl.2010.04.136
69. Puppels GJ, de Mul FF, Otto C, Greve J, Robert-Nicoud M, Arndt-Jovin DJ, et al. Studying single living cells and chromosomes by confocal Raman microspectroscopy. *Nature*. (1990) 347:301–3. doi: 10.1038/347301a0
70. Puppels GJ, Garritsen HS, Segers-Nolten GM, de Mul FF, Greve J. Raman microspectroscopic approach to the study of human granulocytes. *Biophys J*. (1991) 60:1046–56. doi: 10.1016/S0006-3495(91)82142-7
71. Otto C, Sijtsma NM, Greve J. Confocal Raman microspectroscopy of the activation of single neutrophilic granulocytes. *Eur Biophys J*. (1998) 27:582–9. doi: 10.1007/s002490050169
72. van Manen HJ, van Bruggen R, Roos D, Otto C. Single-cell optical imaging of the phagocyte NADPH oxidase. *Antioxidants Redox Signall*. (2006) 8:1509–22. doi: 10.1089/ars.2006.8.1509
73. Ducourthial G, Leclerc P, Mansuryan T, Fabert M, Brevier J, Habert R, et al. Development of a real-time flexible multiphoton microendoscope for label-free imaging in a live animal. *Sci Rep*. (2015) 5:1–9. doi: 10.1038/srep18303
74. Llewellyn ME, Barretto RPJ, Delp SL, Schnitzer MJ. Minimally invasive high-speed imaging of sarcomere contractile dynamics in mice and humans. *Nature*. (2008) 454:784–8. doi: 10.1038/nature07104
75. Williams RM, Flesken-Nikitin A, Ellenson LH, Connolly DC, Hamilton TC, Nikitin AY, et al. Strategies for high resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. *Transl Oncol*. (2010) 3:181–94. doi: 10.1593/tlo.09310
76. Brown CM, Rivera DR, Pavlova I, Ouzounov DG, Williams WO, Mohanan S, et al. *In vivo* imaging of unstained tissues using a compact and flexible multiphoton microendoscope. *J Biomed Opt*. (2012) 17:040505. doi: 10.1117/1.JBO.17.4.040505
77. Pollard JW. Trophic macrophages in development and disease. *Nat Rev Immunol*. (2009) 9:259–70. doi: 10.1038/nri2528
78. Liyanage SE, Gardner PJ, Ribeiro J, Cristante E, Sampson RD, Luhmann UFO, et al. Flow cytometric analysis of inflammatory and resident myeloid populations in mouse ocular inflammatory models. *Exp Eye Res*. (2016) 151:160–70. doi: 10.1016/j.exer.2016.08.007
79. Liu J, Xue Y, Dong D, Xiao C, Lin C, Wang H, et al. CCR2- and CCR2+ corneal macrophages exhibit distinct characteristics and balance inflammatory responses after epithelial abrasion. *Mucosal Immunol*. (2017) 10:1145–59. doi: 10.1038/mi.2016.139
80. Boehm N, Riechardt AI, Wiegand M, Pfeiffer N, Grus FH. Proinflammatory cytokine profiling of tears from dry eye patients by means of antibody microarrays. *Invest Ophthalmol Vis Sci*. (2011) 52:7725–30. doi: 10.1167/iov.11-7266
81. Sawada H, Fukuchi T, Tanaka T, Abe H. Tumor necrosis factor- α concentrations in the aqueous humor of patients with glaucoma. *Invest Ophthalmol Vis Sci*. (2010) 51:903–6. doi: 10.1167/iov.09-4247
82. Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context. *Nat Rev Immunol*. (2014) 14:81–93. doi: 10.1038/nri3600
83. Conway EM, Pikor LA, Kung SHY, Hamilton MJ, Lam S, Lam WL, et al. Macrophages, inflammation, and lung cancer. *Am J Respir Crit Care Med*. (2015) 193:116–30. doi: 10.1164/rccm.201508-1545CI
84. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. *Cancer Res*. (2006) 66:605–12. doi: 10.1158/0008-5472.CAN-05-4005
85. Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. *Blood*. (2009) 113:438–46. doi: 10.1182/blood-2008-04-150789
86. Shen J, Chelvam V, Cresswell G, Low PS. Use of folate-conjugated imaging agents to target alternatively activated macrophages in a murine model of asthma. *Mol Pharm*. (2013) 10:1918–27. doi: 10.1021/mp3006962
87. Blykers A, Schoonooghe S, Xavier C, D'Hoe K, Laoui D, D'Huyvetter M, et al. PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. *J Nucl Med*. (2015) 56:1265–71. doi: 10.2967/jnumed.115.156828
88. Scodeller P, Simón-Gracia L, Kopanchuk S, Tobi A, Kilk K, Säälk P, et al. Precision targeting of tumor macrophages with a CD206 binding peptide. *Sci Rep*. (2017) 7:14655. doi: 10.1038/s41598-017-14709-x
89. Razavian M, Bordenave T, Georgiadis D, Beau F, Zhang J, Golestani R, et al. Optical imaging of MMP-12 active form in inflammation and aneurysm. *Sci Rep*. (2016) 6:38345. doi: 10.1038/srep38345
90. Onda N, Kemmochi S, Morita R, Ishihara Y, Shibutani M. *In vivo* imaging of tissue-remodeling activity involving infiltration of macrophages by a systemically administered protease-activatable probe in colon cancer tissues. *Transl Oncol*. (2013) 6:628–37. doi: 10.1593/tlo.13430
91. Withana NP, Ma X, McGuire HM, Verdoes M, van der Linden WA, Ofori LO, et al. Non-invasive imaging of idiopathic pulmonary fibrosis using cathepsin protease probes. *Sci Rep*. (2016) 6:19755. doi: 10.1038/srep19755
92. Mahalingam SM, Kularatne SA, Myers CH, Gagare P, Norshi M, Liu X, et al. Evaluation of novel tumor-targeted near-infrared probe for fluorescence-guided surgery of cancer. *J Med Chem*. (2018) 61:9637–46. doi: 10.1021/acs.jmedchem.8b01115
93. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. *Acc Chem Res*. (2008) 41:120–9. doi: 10.1021/ar7000815
94. Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, et al. Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages from patients with

- rheumatoid arthritis. *Arthritis Rheum.* (2001) 42:1609–16. doi: 10.1002/1529-0131(199908)42:8<1609::AID-ANR7>3.0.CO;2-L
95. Shen J, Hilgenbrink AR, Xia W, Feng Y, Dimitrov DS, Lockwood MB, et al. Folate receptor-beta constitutes a marker for human proinflammatory monocytes. *J Leukoc Biol.* (2014) 96:563–70. doi: 10.1189/jlb.2AB0713-372R
 96. Han W, Zaynagetdinov R, Yull FE, Polosukhin VV, Gleaves LA, Tanjore H, et al. Molecular imaging of folate receptor β -positive macrophages during acute lung inflammation. *Am J Respir Cell Mol Biol.* (2015) 53:50–9. doi: 10.1165/rcmb.2014-0289OC
 97. Poh S, Chelvam V, Ayala-López W, Putt KS, Low PS. Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases. *Nanomedicine.* (2018) 14:1033–43. doi: 10.1016/j.nano.2018.01.009
 98. Azad AK, Rajaram MVS, Metz WL, Cope FO, Blue MS, Vera DR, et al. γ -tilmanocept, a new radiopharmaceutical tracer for cancer sentinel lymph nodes, binds to the mannose receptor (CD206). *J Immunol.* (2015) 195:2019–29. doi: 10.4049/jimmunol.1402005
 99. Kim JB, Park K, Ryu J, Lee JJ, Lee MW, Cho HS, et al. Intravascular optical imaging of high-risk plaques *in vivo* by targeting macrophage mannose receptors. *Sci Rep.* (2016) 6:22608. doi: 10.1038/srep22608
 100. Geijtenbeek TBH, Torensma R, van Vliet SJ, van Duijnhoven GCF, Adema GJ, van Kooyk Y, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. *Cell.* (2000) 100:575–85. doi: 10.1016/S0092-8674(00)80693-5
 101. Chakravarty R, Goel S, Cai W. Nanobody: the “magic bullet” for molecular imaging? *Theranostics.* (2014) 4:386–98. doi: 10.7150/thno.8006
 102. Devoogdt N, Xavier C, Hernot S, Vaneycken I, D’Huyvetter M, De Vos J, et al. Molecular imaging using nanobodies: a case study. In: Saerens D, Muyldermans S, editors. *Single Domain Antibodies*. 911. *Methods in Molecular Biology*. Totowa, NJ: Humana Press (2012). p. 559–67. doi: 10.1007/978-1-61779-968-6_35
 103. Movahedi K, Schoonooghe S, Laoui D, Houbrecken I, Waelput W, Breckpot K, et al. Nanobody-based targeting of the macrophage mannose receptor for effective *in vivo* imaging of tumor-associated macrophages. *Cancer Res.* (2012) 72:4165–77. doi: 10.1158/0008-5472.CAN-11-2994
 104. Debie P, Van Quathem J, Hansen I, Bala G, Massa S, Devoogdt N, et al. Effect of dye and conjugation chemistry on the biodistribution profile of near-infrared-labeled nanobodies as tracers for image-guided surgery. *Mol Pharm.* (2017) 14:1145–53. doi: 10.1021/acs.molpharmaceut.6b01053
 105. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. *Cell.* (2010) 141:52–67. doi: 10.1016/j.cell.2010.03.015
 106. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. *Proc Natl Acad Sci USA.* (2004) 101:17867–72. doi: 10.1073/pnas.0408191101
 107. Miampamba M, Liu J, Harootunian A, Gale AJ, Baird S, Chen SL, et al. Sensitive *in vivo* visualization of breast cancer using ratiometric protease-activatable fluorescent imaging agent, AVB-620. *Theranostics.* (2017) 7:3369–86. doi: 10.7150/thno.20678
 108. Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. *Respir Res.* (2000) 2:3. doi: 10.1186/rr33
 109. Dean RA, Cox JH, Bellac CL, Doucet A, Starr AE, Overall CM. Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. *Blood.* (2008) 112:3455–64. doi: 10.1182/blood-2007-12-129080
 110. Bordenave T, Helle M, Beau F, Georgiadis D, Tepshi L, Bernes M, et al. Synthesis and *in vitro* and *in vivo* evaluation of MMP-12 selective optical probes. *Bioconj Chem.* (2016) 27:2407–17. doi: 10.1021/acs.bioconjchem.6b00377
 111. Afik R, Zigmund E, Vugman M, Klepfish M, Shimshoni E, Pasmanik-Chor M, et al. Tumor macrophages are pivotal constructors of tumor collagenous matrix. *J Exp Med.* (2016) 213:2315–31. doi: 10.1084/jem.20151193
 112. Ofori LO, Withana NP, Prestwood TR, Verdoes M, Brady JJ, Winslow MM, et al. Design of protease activated optical contrast agents that exploit a latent lysosomotropic effect for use in fluorescence-guided surgery. *ACS Chem Biol.* (2015) 10:1977–88. doi: 10.1021/acschembio.5b00205
 113. Verdoes M, Edgington LE, Scheeren FA, Leyva M, Blum G, Weiskopf K, et al. A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages. *Chem Biol.* (2012) 19:619–28. doi: 10.1016/j.chembiol.2012.03.012
 114. Sevick-Muraca EM, Zhu B. The need for performance standards in clinical translation and adoption of fluorescence molecular imaging. *Med Phys.* (2013) 40:040402. doi: 10.1118/1.4789499

Conflict of Interest Statement: MB and KD are shareholders of Edinburgh Molecular Imaging.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Birch, Campbell, Bradley and Dhaliwal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.